This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Momentum Monday: Inflation, Earnings, and Breakouts
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Monday to get the scoop on market-leading stocks and major economic news
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates
by Zacks Equity Research
The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.
Q4 Earnings Results Reflect Stability
by Sheraz Mian
The picture emerging from the Q4 earnings season thus far has been good enough - not great, but definitely not bad either. Next week, we shift into a much higher gear, with 71 S&P 500 members scheduled to report.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Johnson & Johnson (JNJ) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Johnson & Johnson (JNJ) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) concluded the recent trading session at $160.43, signifying a -0.06% move from its prior day's close.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More
by Kinjel Shah
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
The Zacks Analyst Blog Highlights Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR
by Zacks Equity Research
Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR are part of the Zacks top Analyst Blog.
Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU) and The Southern Company (SO).
Will Q4 Earnings Push Dow ETF Higher?
by Sweta Killa
Let's delve deeper into the probable fourth-quarter earnings picture that will likely aid Dow ETF in the coming days.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $161.63, representing a +0.06% change from its previous close.
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
by Zacks Equity Research
J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.
Biotech ETFs Stage Solid Comeback at the Start of 2024
by Sweta Killa
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
by Zacks Equity Research
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
by Zacks Equity Research
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $156.58, indicating a +0.15% shift from the previous trading day.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $155.44, marking a +0.18% move from the previous day.